Cyclophosphamide vs placebo
Adverse events: haematuria 12‐month · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide may leads to higher adverse events: haematuria 12‐month compared with placebo (low certainty).
1 finding from 1 review
- Cyclophosphamide for connective tissue disease–associated interstitial lung disease 2018 · Cochrane Headline outcomes onlyOR 2.6 [1.12, 6.03]2 studies · 203 participantsLow